| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 30, 2014
MINNEAPOLIS - March 6, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the European Patent Office (EPO) has invalidated, in its entirety, the Edwards Lifesciences EP2055266 Spenser patent...
-
Mar 30, 2014Six-Month Analysis of First 1,000 Patients Enrolled in Real-World Patient Registry Presented at ACC.14
MINNEAPOLIS and WASHINGTON, D.C. - March 30, 2014 - Medtronic, Inc. (NYSE: MDT), announced today further analysis of six-month follow-up data from the first 1,000 patients enrolled in the Global...
-
Mar 30, 2014Has Repaired Hearts of 6,000+ Patients; More Than Half Are Children
MINNEAPOLIS and WASHINGTON - March 30, 2014 - Medtronic, Inc. (NYSE: MDT), today announced the one-year results of the Melody® Transcatheter Pulmonary Valve (TPV) U.S. Post-Approval Study, which...
-
Mar 29, 2014Medtronic CoreValve® System Results Superior to Open-Heart Surgery at One Year in U.S. Pivotal TrialCoreValve High Risk Study: FDA Determines Expert Panel Not Required
MINNEAPOLIS and WASHINGTON - March 29, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the CoreValve® System showed results superior to surgical aortic valve replacement (SAVR) at one...
-
Mar 29, 2014Medtronic Commits to Further Clinical Investigation and Determining Path Forward for Next U.S. IDE with FDA
MINNEAPOLIS and WASHINGTON, DC - March 29, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the full results of the SYMPLICITY HTN-3 clinical trial, which were presented today in late-breaking...
-
Mar 28, 2014
DENVER, Colo. and DUBLIN, Ireland – March 28, 2014 – In a move aimed at giving nursing professionals the tools they need to address rapidly changing practices and cost structures, the AORN...
-
Mar 27, 2014Study Will Assess Defibrillator Therapy in Patients Most At-Risk for SCA
Minneapolis - March 27, 2014 -Medtronic, Inc. (NYSE:MDT) today announced the first patients were enrolled in the Improve SCA Clinical Study, a first-of-its-kind study that will identify patients...
-
Mar 25, 2014
DUBLIN--(BUSINESS WIRE)--Mar. 25, 2014-- An innovative Covidien (NYSE: COV) technology is effective at treating Barrett’s esophagus (a precancerous condition of the esophagus), according to a...
-
Mar 19, 2014
DUBLIN, Ireland--(BUSINESS WIRE)--Mar. 19, 2014-- Covidien plc (NYSE:COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.32 per ordinary share. The...
-
Mar 19, 2014
DUBLIN, Ireland--(BUSINESS WIRE)--Mar. 19, 2014-- Covidien plc (NYSE: COV) announced the results from today’s Annual General Meeting. Seven proposals were on the meeting agenda: Election of...